GenSight Biologics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	0	1.5	1.27	2.58	5.28
Other Revenue	0.65	1.13	1.7	2.28	2.43
Revenue	0.65	2.63	2.96	4.87	7.71
Revenue Growth (YoY)	-75.16%	-11.44%	-39.07%	-36.89%	3.62%
Gross Profit	0.65	2.63	2.96	4.87	7.71
Selling, General & Admin	5.27	6.07	13.3	13.36	12.92
Research & Development	6.44	12.37	19.36	19.34	22.92
Operating Expenses	11.71	18.44	32.66	32.7	35.84
Operating Income	-11.05	-15.81	-29.7	-27.84	-28.13
Interest Expense	-0.99	-1.55	-3.15	-2.65	-2.17
Currency Exchange Gain (Loss)	-	0.19	-0.21	0.65	0.37
Other Non Operating Income (Expenses)	-	3.2	6.84	2.21	1.31
EBT Excluding Unusual Items	-12.04	-13.98	-26.22	-27.62	-28.62
Pretax Income	-12.04	-13.98	-26.22	-27.62	-28.62
Income Tax Expense	-0.01	0.02	-	0.01	0
Net Income	-12.04	-14	-26.22	-27.63	-28.62
Net Income to Common	-12.04	-14	-26.22	-27.63	-28.62
Shares Outstanding (Basic)	148	96	48	46	45
Shares Outstanding (Diluted)	148	96	48	46	45
Shares Change (YoY)	54.87%	98.18%	4.29%	2.61%	28.54%
EPS (Basic)	-0.08	-0.15	-0.54	-0.60	-0.63
EPS (Diluted)	-0.08	-0.15	-0.54	-0.60	-0.63
Free Cash Flow	-9.17	-12.94	-24.67	-34.01	-17.17
Free Cash Flow Per Share	-0.06	-0.14	-0.51	-0.73	-0.38
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-1695.40%	-602.44%	-1001.86%	-572.15%	-364.86%
Profit Margin	-1846.01%	-533.37%	-884.62%	-567.83%	-371.21%
Free Cash Flow Margin	-1406.44%	-492.88%	-832.42%	-698.97%	-222.74%
EBITDA	-10.59	-15.65	-27.52	-26.77	-27.2
D&A For EBITDA	0.47	0.16	2.18	1.06	0.93
EBIT	-11.05	-15.81	-29.7	-27.84	-28.13
Revenue as Reported	0.65	2.63	2.96	4.87	7.71

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.